Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients

Diseases of the Esophagus

Volumn 25, Issue 3, 2012, Pages 242-249

  lukaszewicz Zajac M ^a   Mroczko, B ^a   Kozlowski M ^a   Niklinski J ^a   Laudanski J ^a   Szmitkowski, M ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Esophageal cancer; Interleukin 6; Tumor marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; INTERLEUKIN 6; SQUAMOUS CELL CANCER ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOLUMINESCENCE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DISTANT METASTASIS; ENZYME IMMUNOASSAY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; AREA UNDER CURVE; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859640183     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2011.01242.x     Document Type: Article

References (22)

1. Coussens L, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
2. Vakkila J, Lotze M. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004; 4: 641-8.
3. Zeh H R, Lotze M. Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother 2005; 28: 1-9.
4. Kim D, Oh S, Kwon H etal. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 2009; 9: 155-64.
5. Groblewska M, Mroczko B, Wereszczyńska-Siemiatkowska U etal. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med 2008; 46: 1423-8.
6. Mroczko B, Groblewska M, Gryko M, Kedra B, Szmitkowski M. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J Clin Lab Anal 2010; 24: 256-61.
7. Oka M, Yamamoto K, Takahashi M etal. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 1996; 56: 2776-80.
8. Orringer M, Marshall B, Chang A, Lee J, Pickens A, Lau C. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg 2007; 246: 363-3724.
9. Siewert J, Stein H, Feith M, Bruecher B, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1000 consecutive resections at a single center in the Western world. Ann Surg 2001; 234: 360-9.
10. Motoyama S, Miura M, Hinai Y etal. CRP genetic polymorphism is associated with lymph node metastasis in thoracic esophageal squamous cell cancer. Ann Surg Oncol 2009; 16: 2479-85.
11. Motoyama S, Miura M, Hinai Y etal. C-reactive protein 1059G>C genetic polymorphism influences serum C-reactive protein levels after esophagectomy in patients with thoracic esophageal cancer. J Am Coll Surg 2009; 209: 477-83.
12. Guillem P, Triboulet J. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 2005; 18: 146-50.
13. Oka M, Iizuka N, Yamamoto K etal. The influence of interleukin-6 on the growth of human esophageal cancer cell lines. J Interferon Cytokine Res 1996; 16: 1001-6.
14. Oka M, Hirose K, Iizuka N etal. Cytokine mRNA expression patterns in human esophageal cancer cell lines. J Interferon Cytokine Res 1995; 15: 1005-9.
15. Huang S, Wu M, Wang H, Yang C, Kuo M, Lin J. Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma. J Gastroenterol Hepatol 2002; 17: 1165-9.
16. Deans D, Wigmore S, Gilmour H, Paterson-Brown S, Ross J, Fearon K. Elevated tumour interleukin-1beta is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer. Br J Cancer 2006; 95: 1568-75.
17. Jass J R, Sobin L H. WHO International Histological Classification of Tumors. Histological Typing of Intestinal Tumors. New York: Springer-Verlag, 1989.
18. Mroczko B, Kozłowski M, Groblewska M etal. The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients. Clin Chim Acta 2008; 389: 61-6.
19. Crew K, Neugut A. Epidemiology of upper gastrointestinal malignancies. Semin Oncol 2004; 31: 450-64.
20. Vallböhmer D, Lenz H. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus 2006; 19: 425-32.
21. łukaszewicz-Zajac M, Mroczko B, Kozłowski M, Nikliński J, Laudański J, Szmitkowski M. Elevated levels of serum metalloproteinase 9 in patients with esophageal squamous cell carcinoma. Pol Arch Med Wewn 2009; 119: 558-63.
22. łukaszewicz-Zajac M, Mroczko B, Kozłowski M, Nikliński J, Laudański J, Szmitkowski M. Clinical significance of serum macrophage-colony stimulating factor (M-CSF) in esophageal cancer patients and its comparison with classical tumor markers. Clin Chem Lab Med 2010; 48: 1467-73.